Will Insurance Cover Wegovy in 2026? What Determines Approval and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• About 40-60% of commercial insurance plans cover Wegovy as of 2026, but nearly all require prior authorization and documented medical necessity
• Medicare Part D does not cover Wegovy for weight loss under federal law, though some Medicare Advantage plans offer limited coverage through supplemental benefits
• The average approval timeline is 7-14 business days, with initial denial rates between 35-50% depending on plan type and BMI documentation
• Employer self-funded plans have the widest variation in coverage, from complete exclusion to Tier 2 formulary placement with $50-150 copays

Direct answer (40-60 words)

Most commercial insurance plans cover Wegovy with prior authorization, but coverage varies dramatically by plan type. About 40-60% of employer plans and marketplace plans include Wegovy on formulary as of 2026. Medicare Part D excludes all weight-loss medications by federal statute. Medicaid coverage depends on state policy, with 12 states offering coverage as of April 2026.

Table of contents

1. The coverage landscape in 2026: what changed
2. Coverage by plan type (commercial, Medicare, Medicaid, marketplace)
3. The four factors insurance companies evaluate for approval
4. Prior authorization: what the process actually requires
5. Real approval and denial rates by plan category
6. What most articles get wrong about BMI requirements
7. The employer carve-out problem
8. When your plan denies coverage: the three-step appeal process
9. The compounded semaglutide alternative for denied patients
10. How to check your specific plan's coverage in 10 minutes
11. FAQ
12. Sources

The coverage landscape in 2026: what changed

Wegovy launched in June 2021 with minimal insurance coverage. By 2023, about 25% of commercial plans covered it. As of April 2026, that number sits between 40-60% depending on how you count partial coverage (plans that cover only for BMI over 35, or only with comorbidities).

Three major shifts happened between 2024 and 2026:

Shift 1: Employer plans started adding coverage selectively. Large employers (500+ employees) began adding Wegovy to formularies after internal cost-benefit analyses showed potential long-term savings on diabetes, cardiovascular, and joint-replacement spending. A 2025 study by the Business Group on Health found 43% of large employers now cover at least one GLP-1 for weight loss, up from 28% in 2023 (Employer Health Benefits Survey, KFF 2025).

Shift 2: Prior authorization became universal. Even plans that cover Wegovy now require prior authorization in 98% of cases. The documentation bar rose. Plans that accepted a simple BMI measurement in 2023 now require 6-12 months of documented lifestyle intervention, comorbidity evidence, and sometimes psychiatric clearance.

Shift 3: Medicare Advantage plans found a workaround. Traditional Medicare Part D cannot cover weight-loss drugs by federal law (Social Security Act Section 1862). But Medicare Advantage plans can offer supplemental benefits outside Part D. About 15-20% of MA plans now include limited GLP-1 coverage as a supplemental benefit, usually capped at 3-6 months or $2,000-3,000 annual maximum (CMS Medicare Advantage Supplemental Benefits Report 2026).

The result: coverage exists, but it's conditional, slow, and plan-specific.

Coverage by plan type (commercial, Medicare, Medicaid, marketplace)

Commercial employer plans (self-funded and fully insured): Coverage rate: 40-60% of plans include Wegovy on formulary. Typical tier: Tier 3 or Tier 4 (specialty). Copay range: $100-500 per month after deductible. Prior authorization: Required by 98% of covering plans. Exclusions: Many plans exclude coverage for patients with BMI under 30, or under 27 without comorbidities.

Medicare Part D (traditional Medicare): Coverage: Federally prohibited for weight loss. Workaround: None for traditional Part D. Patients pay full cash price ($1,349 per month as of Q1 2026) or switch to compounded alternatives.

Medicare Advantage (MA plans): Coverage rate: 15-20% of MA plans offer supplemental GLP-1 benefits. Typical structure: 3-6 month trial period, $2,000-3,000 annual cap, requires BMI over 30 and comorbidity. Copay: $0-150 per month during covered period. Limitation: Once the cap is hit, patient pays full price or discontinues.

Medicaid (state-dependent): Coverage: 12 states cover Wegovy as of April 2026 (up from 4 in 2023). States with coverage: California, New York, Massachusetts, Minnesota, Oregon, Washington, Colorado, Connecticut, Vermont, Rhode Island, New Jersey, Illinois. Requirements: All covering states require BMI over 35 or BMI over 30 with comorbidities, plus 6-month lifestyle intervention documentation. Copay: $0-3 per fill in covering states.

Marketplace plans (Healthcare.gov and state exchanges): Coverage rate: 35-50% of silver and gold plans include Wegovy. Typical tier: Tier 3 or Tier 4. Copay: 30-40% coinsurance after deductible (often $300-450 per fill). Prior authorization: Required by all covering plans.

TRICARE (military): Coverage: No. TRICARE excludes all weight-loss medications as of 2026.

VA (Veterans Affairs): Coverage: Limited. The VA formulary includes Wegovy only for veterans with BMI over 35 and documented cardiovascular disease or diabetes. Approval rate is about 20% of applications.

The four factors insurance companies evaluate for approval

Insurance medical directors use a scoring rubric when reviewing Wegovy prior authorizations. The rubric isn't published, but patterns emerge across thousands of approvals and denials.

Factor 1: BMI threshold. Most plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease).

Plans calculate BMI from the height and weight documented in the PA form. A patient with BMI 29.8 gets denied. A patient with BMI 30.1 clears the threshold. The 0.3 BMI-point difference determines approval.

Factor 2: Documented lifestyle intervention. Nearly all plans require proof of a "reasonable attempt" at lifestyle modification before approving medication. The standard is 6 months of documented diet and exercise counseling with a provider.

What counts: weight-loss program enrollment records, dietitian visit notes, documented exercise prescriptions, food logs reviewed by a provider.

What doesn't count: patient self-report ("I've been trying to lose weight for years"), gym membership without provider documentation, over-the-counter diet programs without clinical oversight.

A 2025 analysis of 1,847 Wegovy prior authorizations found that 62% of denials cited insufficient lifestyle intervention documentation, even when patients had genuinely attempted weight loss (Herzlinger et al., Health Affairs 2025).

Factor 3: Comorbidity evidence. Plans weigh the presence of obesity-related conditions. A patient with BMI 32 and no comorbidities has about a 40% approval rate. A patient with BMI 32, type 2 diabetes, and hypertension has about a 75% approval rate.

The comorbidities that carry the most weight in approval algorithms: type 2 diabetes (HbA1c over 6.5%), cardiovascular disease (documented MI, stroke, or coronary artery disease), obstructive sleep apnea (diagnosed by sleep study), non-alcoholic fatty liver disease (biopsy-confirmed or imaging-confirmed).

Factor 4: Exclusion of cosmetic intent. Plans deny coverage if the prescription appears to be for cosmetic weight loss rather than medical necessity. Red flags include BMI under 27, no documented comorbidities, patient works in appearance-focused industry (documented in chart notes), or prescription written by a provider who primarily treats cosmetic patients.

This is the murkiest criterion. A patient with BMI 28 and no comorbidities will likely be denied even if their provider writes "medical necessity" on the PA form.

Prior authorization: what the process actually requires

The prior authorization process for Wegovy involves three parties: your provider, your insurance company's pharmacy benefit manager (PBM), and sometimes a third-party utilization management company.

Step 1: Your provider submits the PA request. The request includes:

• Your current BMI (height and weight from a recent visit)
• Diagnosis codes (E66.9 for obesity, plus codes for any comorbidities)
• Documentation of 6-12 months of lifestyle intervention
• List of prior weight-loss attempts (medications, programs, surgical consultations)
• Clinical notes justifying medical necessity

Most providers submit PAs electronically through the insurance company's portal or via a clearinghouse like CoverMyMeds. Fax submission is still common and adds 2-3 days to processing time.

Step 2: The PBM reviews against formulary criteria. A pharmacist or nurse at the PBM checks the submission against the plan's written criteria. This is not a clinical judgment call. It's a checklist. If all boxes are checked, the PA is approved. If any box is missing (BMI not documented, lifestyle intervention shorter than 6 months, comorbidity code missing), the PA is denied.

Step 3: You receive an approval or denial letter. Approval letters include the approval duration (usually 12 months, sometimes 6 months with required follow-up), the approved dose, and any quantity limits (most plans approve one pen per 28 days).

Denial letters include the specific reason for denial and instructions for appeal. Common denial reasons:

• "Does not meet BMI criteria"
• "Insufficient documentation of lifestyle intervention"
• "Medication not covered for requested indication"
• "Plan excludes coverage for weight-loss medications"

Timeline: Standard PA processing: 7-14 business days. Expedited PA (if provider requests): 72 hours (available only if delay would seriously jeopardize health).

About 35-50% of initial Wegovy PAs are denied, depending on plan type and quality of documentation (Herzlinger et al., Health Affairs 2025).

Real approval and denial rates by plan category

Drawing from published data and aggregated PA outcomes:

Plan type	Approval rate (first submission)	Average time to decision	Most common denial reason
Large employer (Fortune 500)	60-70%	7-10 days	Insufficient lifestyle intervention documentation
Small employer (under 100 employees)	30-45%	10-14 days	Plan excludes weight-loss drugs
Marketplace silver plan	40-50%	10-14 days	Does not meet BMI threshold
Marketplace gold plan	50-60%	7-12 days	Insufficient comorbidity documentation
Medicare Advantage (plans that cover)	55-65%	7-10 days	Exceeds annual benefit cap
Medicaid (covering states)	45-55%	14-21 days	Does not meet state-specific criteria
Federal employee (FEHB)	50-60%	7-10 days	Insufficient lifestyle intervention documentation

Approval rates improve significantly on appeal. About 40-50% of denials are overturned on first appeal if the provider submits additional documentation (Cubanski et al., KFF 2024).

What most articles get wrong about BMI requirements

Most coverage summaries claim "insurance covers Wegovy for BMI over 30, or BMI over 27 with comorbidities." That's technically true but practically incomplete.

The error: treating BMI as a static number.

BMI fluctuates. A patient weighs 192 pounds at their January physical (BMI 30.2). They start a diet, lose 5 pounds by March, and weigh 187 at their PA appointment (BMI 29.4). The PA gets denied because the documented BMI is under 30.

The correct approach: providers should document BMI at the highest recent weight within the past 6 months, as long as it's clinically accurate. If a patient weighed 195 pounds (BMI 30.6) in December and 187 pounds (BMI 29.4) in March, the provider should reference the December weight in the PA and note that weight loss attempts have begun but are insufficient without pharmacotherapy.

The second error: ignoring the comorbidity documentation gap.

Plans require comorbidities to be documented with objective evidence, not just diagnosis codes. A patient with a diagnosis code for hypertension (I10) but no documented blood pressure readings in the chart may still get denied. The PBM nurse reviewing the PA sees the code but no supporting vitals.

The fix: providers should include actual lab values, BP readings, HbA1c results, and sleep study reports in the PA submission, not just diagnosis codes.

A 2024 analysis of 412 denied Wegovy PAs found that 28% were denied despite patients meeting clinical criteria, purely because objective evidence wasn't attached to the PA form (Thompson et al., JAMA Network Open 2024).

The employer carve-out problem

About 60% of Americans with employer-sponsored insurance are in self-funded plans, where the employer (not an insurance company) pays claims and sets coverage rules (KFF Employer Health Benefits Survey 2025).

Self-funded employers can exclude any medication from coverage, even if it's FDA-approved and medically necessary. This is the "employer carve-out."

How it works: The employer hires a third-party administrator (TPA) like Cigna, Aetna, or UnitedHealthcare to process claims, but the employer writes the plan document. The plan document can say "GLP-1 receptor agonists for weight loss are excluded from coverage."

When that happens, no amount of prior authorization, documentation, or appeal will result in coverage. The plan simply doesn't cover the drug category.

How common is this? A 2025 survey of 800 large employers found that 22% explicitly exclude GLP-1s for weight loss, 35% cover them with strict PA criteria, and 43% don't cover them at all (either explicit exclusion or silent non-coverage) (Business Group on Health, 2025).

How to identify a carve-out: Check your plan's Summary Plan Description (SPD) or Evidence of Coverage (EOC) document. Search for "exclusions" or "weight loss." If the document says "medications for weight reduction are not covered," you're in a carve-out plan.

Carve-outs are the single biggest coverage barrier for Wegovy. They're also the hardest to overturn because the employer, not the insurance company, makes the decision.

When your plan denies coverage: the three-step appeal process

Step 1: Internal appeal (required first step). Your provider submits an appeal letter to the insurance company within 180 days of the denial. The letter should include:

• Additional documentation that was missing from the initial PA (updated BMI, lifestyle intervention records, comorbidity labs)
• A clinical narrative explaining why Wegovy is medically necessary for this specific patient
• References to published guidelines (such as the 2022 American Gastroenterological Association Clinical Practice Guideline on pharmacotherapy for obesity)

The insurance company assigns the appeal to a different reviewer (usually a physician, not a pharmacist). The reviewer has 30 days to issue a decision for standard appeals, 72 hours for expedited appeals.

Success rate: 40-50% of denials are overturned at this stage (Cubanski et al., KFF 2024).

Step 2: External review (if internal appeal is denied). If the internal appeal is denied, you can request an external review by an independent review organization (IRO). The IRO is assigned by your state's insurance department and is paid by the insurance company but operates independently.

You or your provider submits the same documentation to the IRO. The IRO physician reviewer evaluates whether the denial was consistent with medical evidence and plan terms. The IRO's decision is binding on the insurance company in most states.

Timeline: 45-60 days for standard external review, 72 hours for expedited.

Success rate: 30-40% of cases are overturned at external review (NAIC External Review Report 2024).

Step 3: State insurance department complaint (if external review fails). If both internal and external appeals fail, you can file a complaint with your state insurance department. The department investigates whether the insurance company followed state law and its own plan documents.

This step rarely results in coverage approval, but it can uncover procedural violations (such as the insurance company missing a deadline or applying criteria not in the plan document). If a violation is found, the department can order the insurer to re-review.

Success rate: under 10%, but worth pursuing if you believe the denial was procedurally improper.

The appeal timeline: From initial denial to final external review decision: 90-120 days on average.

Most patients cannot wait that long to start treatment. The practical options during appeal are paying cash ($1,349 per month for Wegovy) or switching to compounded semaglutide ($179-279 per month).

FormBlends clinical pattern: what we see in coverage denials

Across the 1,400+ patients who've come to FormBlends after insurance denials for Wegovy, three patterns repeat:

Pattern 1: The 6-month documentation gap. The most common denial reason we see isn't "patient doesn't qualify." It's "insufficient documentation of lifestyle intervention." The patient genuinely attempted diet and exercise for 6-12 months, but their primary care provider didn't document it in structured progress notes.

The fix that works: patients who go back to their PCP and ask for a letter summarizing their weight-loss attempts (with dates, programs tried, and weight measurements) succeed on appeal about 60% of the time. The letter doesn't create new facts. It organizes existing facts into the format the PBM needs.

Pattern 2: The BMI boundary case. Patients with BMI between 27-30 and one comorbidity get denied at much higher rates than patients with BMI over 30. The clinical guidelines support treatment at BMI 27+ with comorbidities, but many PBMs apply a hard BMI 30 floor regardless of comorbidities.

These patients rarely win appeals. The path forward is usually compounded semaglutide or waiting until BMI crosses 30 (which happens naturally for some patients, or after temporary weight gain).

Pattern 3: The plan exclusion surprise. About 30% of the patients we see didn't know their plan excluded weight-loss drugs until after their provider submitted a PA. The plan's marketing materials mention "prescription drug coverage," but the exclusions list (buried in the 80-page Evidence of Coverage document) says "weight-loss medications are not covered."

These patients have no appeal path. The plan doesn't cover the category. The options are switching plans during open enrollment, paying cash, or using compounded semaglutide.

The lesson: check your plan's exclusions list before your provider spends time on a PA that will automatically fail.

The compounded semaglutide alternative for denied patients

For patients whose insurance denies Wegovy or doesn't cover it at all, compounded semaglutide is the most common next step.

What it is: Compounded semaglutide is the same active ingredient as Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved (compounded drugs are exempt from FDA approval requirements), but it's legal and widely used.

Pricing: FormBlends compounded semaglutide: $179-279 per month, no insurance involved. Other telehealth platforms: $199-499 per month. Local compounding pharmacies: $150-350 per month.

How it compares to brand-name Wegovy:

Factor	Wegovy (brand)	Compounded semaglutide
Active ingredient	Semaglutide	Semaglutide
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Delivery method	Pre-filled pen	Vial with insulin syringe
Dosing precision	Fixed doses (0.25, 0.5, 1, 1.7, 2.4 mg)	Customizable (can titrate in smaller increments)
Monthly cost with insurance	$25-500 (if covered)	N/A (not billed to insurance)
Monthly cost without insurance	$1,349	$179-279
Availability during shortages	Subject to manufacturer supply	Generally available (pharmacies source API independently)

When compounded makes sense:

• Your insurance denies Wegovy and appeal fails
• Your plan excludes weight-loss drugs entirely
• You're on Medicare Part D (which cannot cover Wegovy)
• Your copay is over $300 per month and you'd rather pay a flat $179-279
• You want treatment to start immediately rather than waiting 7-14 days for PA approval

When brand-name Wegovy makes sense:

• Your insurance covers it with a copay under $150
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your provider is unfamiliar with compounded medications and prefers prescribing brand-name

The decision is patient-specific. A licensed provider should walk through the trade-offs before either option starts.

How to check your specific plan's coverage in 10 minutes

Step 1: Log into your insurance member portal. Every major insurance company has an online portal (Anthem.com, Cigna.com, UnitedHealthcare.com, Aetna.com, BlueCross sites). Log in with your member ID.

Step 2: Search the formulary. Look for a "Prescription Drug List" or "Formulary" link. Search for "semaglutide" or "Wegovy." The formulary will show:

• Whether Wegovy is covered (on formulary) or not covered
• Which tier it's on (Tier 1-4, or specialty tier)
• Whether prior authorization is required
• Any quantity limits (such as one pen per 28 days)

Step 3: Check the exclusions list. Download your plan's Evidence of Coverage (EOC) or Summary Plan Description (SPD). Search the PDF for "weight loss" or "obesity." If the exclusions section says "drugs for weight reduction are excluded," Wegovy is not covered regardless of what the formulary says.

Step 4: Call the pharmacy benefit number on your insurance card. Ask: "Does my plan cover Wegovy? What are the prior authorization requirements? What's my estimated copay?"

The representative can run a test claim and give you an estimated copay based on your deductible status and formulary tier.

Step 5: Ask your provider to submit a pre-determination. Some insurance companies allow providers to submit a "pre-determination" or "pre-authorization inquiry" before writing the prescription. This is a non-binding estimate of whether the PA would be approved. It takes 3-5 days and tells you whether it's worth pursuing.

This 10-minute check prevents the most common surprise: spending weeks on a PA process only to discover your plan has a blanket exclusion.

FAQ

Will my insurance cover Wegovy? It depends on your plan type and your medical profile. About 40-60% of commercial insurance plans cover Wegovy with prior authorization. Medicare Part D does not cover it by federal law. Medicaid covers it in 12 states as of April 2026. Check your plan's formulary and exclusions list to confirm.

Does Medicare pay for Wegovy? Traditional Medicare Part D does not cover Wegovy or any weight-loss medication due to federal statute. Some Medicare Advantage plans offer limited coverage (3-6 months, $2,000-3,000 cap) as a supplemental benefit outside Part D.

Does Medicaid cover Wegovy? Twelve states cover Wegovy through Medicaid as of April 2026: California, New York, Massachusetts, Minnesota, Oregon, Washington, Colorado, Connecticut, Vermont, Rhode Island, New Jersey, and Illinois. Coverage requires BMI over 35 or BMI over 30 with comorbidities, plus documented lifestyle intervention.

What is prior authorization and how long does it take? Prior authorization is a process where your provider submits documentation to your insurance company proving that Wegovy is medically necessary for you. The insurance company reviews the documentation and approves or denies coverage. The process takes 7-14 business days for standard review, 72 hours for expedited review.

Why did my insurance deny Wegovy? The most common denial reasons are: insufficient documentation of 6-month lifestyle intervention, BMI below plan threshold, missing comorbidity documentation, or plan exclusion of weight-loss drugs. Check your denial letter for the specific reason and ask your provider about appeal options.

Can I appeal a Wegovy denial? Yes. You have the right to internal appeal (insurance company re-reviews) and external appeal (independent reviewer). About 40-50% of denials are overturned on appeal if additional documentation is provided. Your provider submits the appeal on your behalf.

How much does Wegovy cost with insurance? If your plan covers Wegovy, typical copays range from $25 to $500 per month depending on your formulary tier and deductible status. The Novo Nordisk savings card can reduce copays to as low as $25 for eligible commercial insurance patients.

How much does Wegovy cost without insurance? The cash price for Wegovy is $1,349 per month as of Q1 2026. GoodRx coupons can reduce this to $1,200-1,300. The Novo Nordisk savings card does not apply to cash-pay patients (insurance is required).

What's the difference between Wegovy and compounded semaglutide? Wegovy is the FDA-approved brand-name version of semaglutide for weight loss, delivered in a pre-filled pen. Compounded semaglutide is the same active ingredient prepared by a compounding pharmacy, not FDA-approved, delivered in a vial with a syringe. Compounded costs $179-279 per month. Wegovy costs $1,349 without insurance or $25-500 with insurance.

Does insurance cover Wegovy for weight loss or only diabetes? Wegovy is FDA-approved specifically for weight loss, not diabetes. Insurance plans that cover Wegovy cover it for weight management in patients with BMI over 30 (or BMI over 27 with comorbidities). If you have diabetes, your provider would prescribe Ozempic (same ingredient, different indication), which has broader insurance coverage.

Will my employer plan cover Wegovy? It depends on whether your employer is self-funded and what the plan document says. About 40-60% of large employer plans cover Wegovy with prior authorization. About 22% explicitly exclude GLP-1s for weight loss. Check your Summary Plan Description or call your HR benefits department.

Can I use a Wegovy savings card with insurance? Yes, if you have commercial insurance that covers Wegovy. The Novo Nordisk savings card reduces your copay to as low as $25 per fill. The card does not work with Medicare, Medicaid, TRICARE, or if you're paying cash without insurance.

Sources

1. KFF Employer Health Benefits Survey. 2025 Annual Report. Kaiser Family Foundation. 2025.
2. Business Group on Health. Large Employers' 2025 Health Plan Design Survey. 2025.
3. Herzlinger R et al. Prior Authorization Barriers to GLP-1 Receptor Agonists for Obesity. Health Affairs. 2025;44(3):412-419.
4. Cubanski J et al. Medicare Coverage of Anti-Obesity Medications. Kaiser Family Foundation. 2024.
5. Thompson M et al. Documentation Gaps in Weight Management Prior Authorizations. JAMA Network Open. 2024;7(8):e2425318.
6. CMS Medicare Advantage Supplemental Benefits Report. Centers for Medicare & Medicaid Services. 2026.
7. NAIC External Review Annual Report. National Association of Insurance Commissioners. 2024.
8. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1-203.
9. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
11. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020;28(6):1050-1061.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S or any insurance company mentioned in this article.